This product is a human IgG1 antibody binding to HLA-B27 heavy-chain homodimers, termed HC-B27, HLA-B272 or B272, particularly recognizing B272 homodimers and which does not recognize or bind HLA-B27 heterotrimers (B27) including HLA-B27 heterotrimers with β2 microglobulin and peptide. The antibody is useful in the studies of HLA-B27 mediated conditions, particularly those associated with B272, the spondyloarthritides, a group of related diseases including ankylosing spondylitis (AS) and reactive arthritis (ReA or Reiter's syndrome).
Figure 1 HD5 mAb is specific to B272, binds to recombinant B272, and blocks interaction with immunoregulatory cell receptors.
ELISA results showed the specificity of HD5 and HD6 to B272 homodimers when challenged for different recombinant HLA class I complexes (-A1,-B7,-B13,-C7,-B27, and-B272).
Belaunzaran, O. M., Kleber, S., Schauer, S., Hausmann, M., Nicholls, F., Van den Broek, M., ... & Shaw, J. (2015). HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. Plos one , 10 (6), e0130811.
Figure 2 Representative flow cytometry analysis of HD5 and control antibodies (IgG1 Isotype, W6/32, ME1, HC10, and HD6) binding to LBL721.
HD5 binds specifically to cell-surface B272 homodimers expressed in human 220 B cell lines.
Belaunzaran, O. M., Kleber, S., Schauer, S., Hausmann, M., Nicholls, F., Van den Broek, M., ... & Shaw, J. (2015). HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. Plos one , 10 (6), e0130811.
Figure 3 HD5 mAb blocks interaction of B272 to leukocytes and modulates activation of CD4+ T-cells by B272.
Pre-incubation of HD5 or HC10 with B272(1x)-tetramers partially blocked interactions with cells when compared to control antibodies.
Belaunzaran, O. M., Kleber, S., Schauer, S., Hausmann, M., Nicholls, F., Van den Broek, M., ... & Shaw, J. (2015). HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. Plos one , 10 (6), e0130811.
Figure 4 Representative results from 1 of 3 experiments are shown.
Diaminobenzidine‐stained sections of fixed .
Payeli, S. K., Kollnberger, S., Marroquin Belaunzaran, O., Thiel, M., McHugh, K., Giles, J., ... & Keidel, S. (2012). Inhibiting HLA–B27 homodimer–driven immune cell inflammation in spondylarthritis. Arthritis & Rheumatism , 64 (10), 3139-3149.
Figure 5 Western blot analysis of HLA class I heavy chains after surface immunoprecipitation of LBL721.
Immunoprecipitation samples were tested by sodium dodecyl sulfate–polyacrylamide gel electrophoresis under nonreducing conditions (left) and reducing conditions (right).
Payeli, S. K., Kollnberger, S., Marroquin Belaunzaran, O., Thiel, M., McHugh, K., Giles, J., ... & Keidel, S. (2012). Inhibiting HLA–B27 homodimer–driven immune cell inflammation in spondylarthritis. Arthritis & Rheumatism , 64 (10), 3139-3149.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-093CT | Human Anti-HLA-B27 Recombinant Antibody (TAB-093CT) | ELISA, Neut, FC | Human IgG |
TAB-093CT-S(P) | Human Anti-HLA-B27 Recombinant Antibody; scFv Fragment (TAB-093CT-S(P)) | ELISA, Neut, FC | Human scFv |
TAB-093CT-F(E) | Human Anti-HLA-B27 Recombinant Antibody; Fab Fragment (TAB-093CT-F(E)) | ELISA, Neut, FC | Human Fab |
There are currently no Customer reviews or questions for HPAB-J0121-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.